Journal article
Gas entrapping materials for damage control
Advanced drug delivery reviews, Vol.232, 115813
05/2026
DOI: 10.1016/j.addr.2026.115813
PMID: 41724331
Abstract
Gasotransmitters, including nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S), are small endogenously produced signaling molecules that regulate critical intra- and intercellular processes. These gases modulate ion channel activity, gene expression, redox balance, and mitochondrial bioenergetics, while influencing cardiovascular, immune, and nervous system functions. Despite their toxicity at high concentrations, controlled exogenous administration of gasotransmitters has enormous therapeutic potential in conditions such as cancer, cardiovascular disease, sepsis, trauma, and brain injury. A central challenge in translating these molecules into clinical use lies in achieving safe, targeted and tunable delivery. Traditional inhalation methods have evolved with advances in medicinal chemistry, and bioengineering, enabling formulations for oral, parenteral, and localized delivery that exploit the gases' ability to freely diffuse across membranes. This review summarizes current strategies for delivering NO, CO, and H₂S using hydrogels, foams, and solid formulations across skin and gut barrier sites. We discuss the mechanisms governing gasotransmitter activity, factors affecting tissue distribution and reactivity, and the potential clinical utility of these delivery approaches. By highlighting recent preclinical and clinical studies, we provide a framework for optimizing gasotransmitter administration, dosage, and specificity, emphasizing their translational relevance as therapeutic agents.
[Display omitted]
Details
- Title: Subtitle
- Gas entrapping materials for damage control
- Creators
- Paula K.N. Alves - Beth Israel Deaconess Medical CenterIan C. Sutton - University of IowaJames D. Byrne - University of IowaLeo E. Otterbein - Beth Israel Deaconess Medical Center
- Resource Type
- Journal article
- Publication Details
- Advanced drug delivery reviews, Vol.232, 115813
- DOI
- 10.1016/j.addr.2026.115813
- PMID
- 41724331
- NLM abbreviation
- Adv Drug Deliv Rev
- ISSN
- 0169-409X
- eISSN
- 1872-8294
- Publisher
- Elsevier B.V
- Grant note
- Holden Comprehensive Cancer Center at the University of Iowa, National Cancer Institute: P30CA086862, NCI K08CA276908, DP2CA301081 American Cancer Society: IRG-21-141-46
This work was supported by Department of Defense Grants, HT9425-24-1-0769 and HT9425-23-1-1052, and R01 DK128823-01A1 to LEOand the Holden Comprehensive Cancer Center at the University of Iowa, National Cancer Institute P30CA086862, NCI K08CA276908, DP2CA301081, and the American Cancer Society IRG-21-141-46 to JDB.
- Language
- English
- Electronic publication date
- 02/20/2026
- Date published
- 05/2026
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Radiation Oncology
- Record Identifier
- 9985139270502771
Metrics
3 Record Views